Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seeking Alpha. Normally they only keep it on PRO for a day then let anybody look at it. Then they put it back on PRO after a month or 2.
TIK Ended up selling my shares. I don't want to hold through the lawsuit. A stock I owned earlier this year got sued and it was crushed. TIK still has multibagger potential if they beat the lawsuit and get NATO orders in 2017.
GNUS Genius Brands International, Inc. Issues Shareholder Letter. http://finance.yahoo.com/news/genius-brands-international-inc-issues-123000155.html?soc_src=mediacontentsharebuttons&soc_trk=tw Our brands were extremely well received, and our team is now in the process of following up, procuring proposals and starting the process negotiating deals, which we anticipate will conclude over the course of the summer. These deals will generate advances, which will be accompanied by minimum guarantees and a commitment to bring products to market for our various animated characters/brands.
SMDM Some bullish comments in there. Bringing back call center jobs to the US to handle more technical calls. Digital backlog is up as you mentioned. That is good high margin revenue.
LM.V LMDCF Possible new contracts. Management plans to sell the company eventually. http://www.stockhouse.com/companies/bullboard/v.lm/lingo-media-corporation?postid=25021675
Well something like that is hard to predict. If you took the other side of that trade you'd be $1 million in debt. Although most people would just declare bankruptcy at that point.
LM.V LMDCF They were previously focusing on Latin America but just got 2 distributors. One for the US and one for most other countries. This should help speed up growth. Some of this will happen in the 2nd quarter but the 3rd quarter is when we could see really big growth.
LEAT Leatt Partners with Surefoot Store in Whistler, Canada. http://finance.yahoo.com/news/leatt-partners-surefoot-store-whistler-125500913.html
LEAT Leatt Partners with Surefoot Store in Whistler, Canada. http://finance.yahoo.com/news/leatt-partners-surefoot-store-whistler-125500913.html
LTE.C LTCCF Lite Access Technologies Announces New Partner in Yukon, Canada. http://finance.yahoo.com/news/lite-access-technologies-announces-partner-123000657.html
LTE.C LTCCF Lite Access Technologies Announces New Partner in Yukon, Canada. http://finance.yahoo.com/news/lite-access-technologies-announces-partner-123000657.html
Definitely possible on that Netflix Llama Llama deal. I listened to that conference call and he mentioned it was bigger than the Sony deal but couldn't mention how big exactly. So I'm guessing at least $3 million but probably much more. If they keep signing deals they might could do $5 million profit or so within the next 12 months. Andy is a bit of a overpromiser but he keeps mentioning Dreamworks and Marvel. I think that's a bit of a reach but it's the same business model and we could really make some big gains if they can keep up the pace on deals without hurting the quality of the product.
I think the 4th quarter of this year is set up to be a breakout profitable quarter. eventually 1 or 2 of these properties will go viral and be worth tens of millions if not more by itself.
Well over 3000 followers on Youtube with each video getting about 170K views. Decent following for a new show.
Sounds like we may see some deals within a few weeks after this expo. The Netflix and Sony deal sound like big winners. Maybe they can get some traction with their other smaller deals too. I like this business model. It's all high margin recurring revenue.
Sounds like we may see some deals within a few weeks after this expo. The Netflix and Sony deal sound like big winners. Maybe they can get some traction with their other smaller deals too. I like this business model. It's all high margin recurring revenue.
$GNUS Stan Lee's POW! Entertainment, Partner on Ground-Breaking New Property, STAN LEE'S COSMIC CRUSADERS. http://tinyurl.com/hwpau7a
$GNUS Stan Lee's POW! Entertainment, Partner on Ground-Breaking New Property, STAN LEE'S COSMIC CRUSADERS. http://tinyurl.com/hwpau7a
GNUS Genius Brands International Secures Largest Content Licensing Deal in Company History, Marking Milestone in Growth
All-New Animated Preschool Series Based on The NY Times Bestselling Book Franchise, LLAMA LLAMA, to Premiere Globally on Netflix in 2017. http://finance.yahoo.com/news/genius-brands-international-secures-largest-160000970.html
GNUS Genius Brands International Secures Largest Content Licensing Deal in Company History, Marking Milestone in Growth
All-New Animated Preschool Series Based on The NY Times Bestselling Book Franchise, LLAMA LLAMA, to Premiere Globally on Netflix in 2017. http://finance.yahoo.com/news/genius-brands-international-secures-largest-160000970.html
CZO.V CRPOF Our valuation model takes a very conservative stance and does not account for the commercialization of Ceapro’s avenanthramides and/or beta glucan as pharmaceutical products. In the near future, we expect to see results from the studies and trials that are being conducted that support efficacy for treating high cholesterol and inflammation. If these potential candidates are eventually approved, we anticipate material upside to our Ceapro valuation. I definitely expect them to be able to commercialize most if not all of these products. They're raising about $5 million in the private placement so I think they should have the clinical trials and manufacturing expansion easily funded. http://finance.yahoo.com/news/ceapro-inc-announces-brokered-private-110500949.html http://finance.yahoo.com/news/czo-v-ceapro-reports-accelerating-132500549.html
ABRW Still on my watchlist. Almost bought at .40 and .90 I'd like to see a quarter to see what margins are though. Some people think it's worth $4-5 but I consider it risky at the current market cap not knowing what margins will be. It was a huge win for many investors though. Over 3000% gain from the lows of 2014. It could still be a big win from here as they have good management Just too many questions right now for me to get in.
I look at the Canadian and US markets. So I get very few weekdays per year there isn't something going on.
BIOYF I'm invested. With the 2 new drugs possibly doubling the companies revenues in 2-3 years plus organic growth I think it's a very good long term investment.
ANDR I sold it because it did around 800K net income when I was expecting about $5 million due to the language in the previous report. At this point with only 800K net income in the 1st quarter and no new patent agreements in the 2nd quarter it might not even turn a profit in the 2nd quarter.
SCKT Sold it for about a 30% gain. Still think it might run some when it uplists but I like some other stocks more.
SCKT Sold it for about a 30% gain. Still think it might run some when it uplists but I like some other stocks more.
CZO.V CRPOF I agree. I think it's a multibagger from these levels easily. Expanding manufacturing capacity by 5x. That will boost margins. 2 clinical trials. Expanding into 2 huge markets. And the main reason is they have a monopoly with barriers to entry.
OML.V OLNCF Omni-Lite Industries announces Normal Course Issuer Bid They're buying back up to 7% of O/S. About 13x PE and 75% of book value. They're growing earnings about 50% year over year.
CERRITOS, CA , May 19, 2016 /CNW/ - Omni-Lite Industries Canada Inc. ("Omni-Lite" or the "Company") announces that it has submitted to the TSX Venture Exchange ("TSXV) its Notice of Intention to Make a Normal Course Issuer Bid ("Bid"). Pursuant to the Bid, the Company may purchase for cancellation up to 790,000 common shares of the Company which is equal to approximately 7 percent of the 11,081,507 issued and outstanding shares.
The purchases will be made by the Company through Cormark Securities Inc., in accordance with the rules of the TSXV. The consideration paid for any such Common Shares will be the open market price at the time of acquisition. The Company will make no purchases of Common Shares other than open market purchases or other such means approved by the TSXV.
The actual number of Common Shares of the Company that are purchased for cancellation under the Bid, if any, and the timing of such purchases will be determined by management as approved by the Board of Directors of the Company.
To the knowledge of the Company, no director, senior officer or other insider of Omni-Lite currently intends to sell any Common Shares into this Bid. In the case a director, senior officer, or insider does sell any common shares into the Bid, the benefits to any such person would be the same as the benefits available to all other holders whose shares are purchased.
To date, the Company has repurchased and intends to cancel a total of 736,900 common shares pursuant to the previous normal course issuer bid which ends May 25, 2016 .
Purchases may begin on May 26, 2016 and the Bid expires on May 25, 2017 .
Omni-Lite Industries Canada Inc. is a rapidly growing high technology company that develops and manufactures precision components utilized by Fortune 500 companies including Boeing, Airbus, Bombardier, Embraer, Alcoa, Ford, Borg Warner , Chrysler, the U.S. Military, and Nike.
Except for historical information contained herein this document contains forward-looking statements. These statements contain known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CZO.V CRPOF Massive quarter. 137% revenue growth. Big profit. a few clinical trials this year. Expanding manufacturing capicity by 5x. They have a monopoly in their market.
EDMONTON, ALBERTA--(Marketwired - May 18, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the three-months ended March 31, 2016 and provided a business update.
Financial Highlights for the First Quarter 2016
Best first quarter performance with revenues reaching historical highs;
Total sales of $4,064,000 for the quarter ended March 31, 2016 compared to $1,714,000 in 2015, an increase of 137% quarter-over-quarter revenue performance;
Record income from operations of $1,910,000 for the quarter ended March 31, 2016 compared to a loss from operations of $226,000 in 2015;
Net profit after taxes of $1,213,000 for the quarter ended March 31, 2016 compared to a net loss of $194,000 for 2015; and
Cash flows generated from operations for the quarter ended March 31, 2016 of $2,273,000 compared to a cash burn of $173,000 for the same period in 2015.
Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, stated, "We are very pleased with ending the first quarter of 2016 with these exceptional results and aim to continue to drive value in our high-value de-risked base business in cosmeceuticals, which has shown to be a proven result of the effectiveness of our business strategy."
"With these results combined with the recent announcement of the renewal of a long-term agreement with our major distributor, Symrise AG, Ceapro has established a solid base for year-over-year growth. Beyond these excellent financial results, we will continue to develop our pipeline and execute our projects rigorously toward market expansion into the profitable nutraceutical and pharmaceutical sectors as we anticipate top-line data from our beta glucan study and our avenanthramides bioavailability study, and our expected launch of Ceapro's first two clinical studies this year with these two important value drivers."
Recent Corporate Highlights
Presented its PGX Technology at the prestigious 15th European Meeting on Supercritical Fluids;
Received issuance of a U.S. patent for Ceapro's unique and disruptive enabling Pressurized Gas Expanded (PGX) technology covering proprietary methods and use of micro- and nano-sized particles generated by applying PGX supercritical fluid technology;
Signed a Research Agreement with McMaster University for testing of materials using PGX Technology; and
Renewed a major distribution agreement with long-time partner, Symrise AG.
"We fully believe our unique and disruptive enabling PGX technology will expand our reach into additional high-value programs and facilitate beneficial strategic collaborations in a broad range of industrial applications. The broad utility of this technology is an important part of Ceapro's growth strategy," concluded Mr. Gagnon.
Avenanthramides Update
Due to an enabling technology in-licensed from Agriculture Canada, Ceapro successfully produced three batches at the commercial level in its current facility for a next generation of avenanthramides extracted from malted oat. As part of the International Application of the Patent Cooperation Treaty (PCT), the Company has already been issued patents in both Canada and China for avenanthramides resulting from this enabling malting technology.
Ceapro is currently assessing avenanthramides in a bioavailability study with a U.S.-based university to compare low-dose and high-dose avenanthramides. The Company fully expects the bioavailability study to further demonstrate the efficacy of avenanthramides in alleviating exercise-induced inflammation as evidenced by a lack of inflammation biomarkers shown previously in published data from a study in elderly people. If additional positive trends are observed, Ceapro expects to commence its clinical program with avenanthramides as an anti-inflammatory compound before year end.
Beta Glucan Update
Following the successful impregnation study conducted at MIT, Ceapro has initiated a study with the University of Alberta for the development of a prototype formulation for a functional drink whereby the Company has impregnated beta glucan with the well-known co-enzyme Q10 as an energy booster. Ceapro anticipates that the development of the impregnated prototype for functional drink will be completed by the end of 2016.
The Company plans to initiate a pilot clinical study to develop beta glucan as a cholesterol reducer in the third quarter of 2016. Previously existing safety and toxicology studies demonstrate a positive safety profile for beta glucan in more than 200,000 individuals from an industry partner currently commercializing beta glucan as a carrier in a urinary incontinence device. Ceapro will also conduct its own safety studies to assess high purity oral beta glucan during the second quarter of 2016.
PGX Research Programs Update
Ceapro is developing its in-licensed PGX enabling technology at the commercial scale level for all industries and all applications. The Company has been issued a U.S. patent covering proprietary methods and use of micro- and nano-sized particles generated by applying PGX supercritical fluid technology.
The Company has conducted encouraging lab scale research with PGX and analyzed biopolymer samples from commercially available starch, pectin, gums, alginate, and other polymers from various multi-national companies in a broad range of industries. Ceapro is evaluating potential collaborations and alliance opportunities with these companies.
Financial Results for Three Month Period Ended March 31, 2016
Total revenue of $4,064,000 for the three months ended March 31, 2016 compared to $1,714,000 for the three-month period ended March 31, 2015, an increase of 137% primarily as a result of higher sales volumes of beta glucan in Europe and Asia and strong sales of the Company's flagship product, avenanthramides. Total revenues were also positively impacted by a stronger U.S. dollar relative to the Canadian dollar.
Net income before tax was $1,734,000 for the three months ended March 31, 2016 compared to a loss of $230,000 for the same period in 2015.
Net profit after taxes of $1,213,000 for the quarter ended March 31, 2016 compared to a net loss of $194,000 for 2015;
Research and Development investments of $328,000 for the three month period ended March 31, 2016 compared to $106,000 in the 2015 period.
General and Administration expenses of $496,000 for the three months ended March 31, 2016 compared to $802,000 for the same period in 2015. The decrease in G&A in 2016 compared to 2015 is mostly due to lower salaries and benefits expense as the Company did not have a significant option granting so the share-based payment charges were considerably lower. The other significant decrease is related to lower legal fees as the AVAC trial was completed in the first quarter of 2015 and there were no corresponding legal fees in the first quarter of 2016.
Sales and Marketing expenses for the three-months ending March 31, 2016 of only $2,000 compared to $3,000 in 2015, due to the Company's sales strategy to sell mostly through a distribution network.
As of March 31, 2016, the Company had cash and cash equivalents of $1,999,194 as compared to $1,681,125 as of December 31, 2015.
VASO I sold after the 4th quarter results. I just don't trust management on this one. Very high compensation and they barely communicate with shareholders.
MPH.V MCUJF COO was fired because he preferred early stage assets and the CEO prefers to focus on cash flow. Not that good of a quarter but they should have a much better 2nd quarter with the inventory back to normal levels. Also 2 FDA decisions this year on expanding the use of their main drug.
EUO.V EUCTF Thanks for sharing. I agree they are in 3 big markets with big companies as partners. The second half of this year and especially next year should be good for this stock. If SIPCA keeps adding shares it will now show up as insider buys. That would get other people to buy knowing a big company/partner like that is buying in.
CRPOF CZO.V Very nice quarter. They should have enough to finish expanding their manufacturing now. I ended up selling ANDR after their quarter that missed my expectations.
EUO.V EUCTF Lots of new business. They moved into agriculture and are working on new banknote security. Just secured a patent too. My guess is they have a decent bit of new contracts with the fuel marker program but that won't be in a PR due to security reasons.
Net income just over 800K is way below my estimates. I'm selling tomorrow.
NTE.V NMGGF Announces Record Results and Positive Earnings for Q1 2016. .01 EPS for a .14 stock. They did .01 EPS the quarter before too. 2 more quarters like that and they're trading for a PE of 4. I expect earnings to keep growing. http://www.stockhouse.com/news/press-releases/2016/04/28/network-entertainment-announces-record-results-and-positive-earnings-for-q1
WFCF I agree with what you said. They recently expanded into Canada. Signed up 3 auditors and they are talking with customers.
Leatt Corp Financial Results for the First Quarter 2016
Revenue Increases 20 percent; Net Income Increases 109 Percent; First Shipment of DBX 6.0 Carbon and DBX 5.0 Composite helmets; Enthusiastic Acceptance of GPX Helmets in US and Abroad Continues
CAPE TOWN, South Africa, May 13, 2016 /PRNewswire/ -- Leatt Corporation (LEAT) today announced its financial results for the first quarter ended March 31, 2016. Leatt Corporation develops and markets protective equipment and ancillary products for many forms of sports, especially extreme high-velocity sports. All financial numbers are in US dollars.
First Quarter Highlights:
Revenue increased 20 percent;
Net income increased 109 percent;
Initial shipments of DBX 6.0 Carbon and DBX 5.0 Composite helmets for high-velocity cycling and BMX to international customers commenced.
For the three months ended March 31, 2016, revenues were $4.8 million, with net income of $113,000, or $0.02 per share, as compared to revenues of $4.0 million, with net income of $54,000, or $0.01 per share, for the 2015 first quarter.
"We had an excellent 2016 first quarter, highlighted by solid financial results and the successful launch of our new carbon and composite shelled DBX bicycle helmet at the Subaru Sea Otter 2016 Classic in Monterey, California," said CEO Sean Macdonald.
"Revenue increased by 20 percent, and net income doubled in the first quarter, which has typically been our weakest quarter. All our new products continued to soar, although neck braces saw a slight decline."
Chairman of the Board and Head of Research and Development, Dr. Christopher Leatt, added, "The reception accorded our new bicycle helmets—in the press, in the industry and among the riders—was promising. We believe that our new helmets again demonstrate the ingenuity and agility of our entire team in terms of research, design, engineering and product development. Our strategy continues to be to diversify and extend our multi-faceted product line into new sports and markets. We expect that our innovative, lightweight helmets for motocross, extreme sports and now bicycling are a potentially game-changing product for us, with a global market potential."
Mr. Macdonald said that helmet sales accounted for $809,000, or 17% percent of revenues, for the first quarter of 2016. "These helmet revenues are due to the continuation of the initial shipment of our GPX 5.5 Composite and GPX 6.5 Carbon helmets that first shipped to our customers in the United States and abroad during the 2015 fourth quarter. Additionally, we shipped the DBX 6.0 Carbon and DBX 5.0 Composite helmets to our international customers during the 2016 first quarter."
Body Armor sales accounted for $2.19 million and $2.01 million, or 45 percent and 50 percent of revenues for the quarters ended March 31, 2016 and 2015, respectively. "The category was up 9 percent overall, with strong sales in upper body protectors and knee and elbow guards within the category. In addition, our C-Frame knee brace continues to gain traction, and we are now seeing re-orders from our distributors and dealers," said Macdonald.
Sales of the flagship neck brace accounted for $1.59 million and $1.79 million, or 33 percent and 45 percent of revenues, for the quarters ended March 31, 2016 and 2015, respectively.
"In the United States the decrease in neck brace revenues was primarily the result of a decrease in the sales of the MRX pro neck brace for motor sports, which were particularly strong during the 2015 first quarter, but we note that neck brace sales for the motorcycle and bicycle markets in the United States were stable," said Macdonald. The decrease in sales of neck braces to customers outside the United States was caused by the significant strength of the US dollar in relation to the local trading currencies of customers in the respective regions.
Macdonald opined that the strong U.S. dollar may have a more noticeable effect on revenues in more established product categories. Approximately 61% percent of the Company's revenues are derived from sales outside of the United States and the U.S. dollar has made the products more expensive for foreign distributors, dealers and end consumers.
Leatt continued to meet its working capital needs from cash on hand and internally generated cash flow from operations. At March 31, 2016, the Company had cash and cash equivalents of $1.42 million and there was no long term debt.
Business Outlook
"We are very pleased with the initial sales of our innovative line of helmets and believe that they will continue to gain traction with consumers in 2016. They are a potentially game-changing development for the Company that we believe will become as important to the Company as our original neck brace."
The Company previously announced that it was actively developing and expanding its dealer network. "Sales through our B2B portal for dealers in the US is beginning to pick up speed as dealers can easily place orders online. This allows our sales managers to get out of the office and meet dealers and sales representatives face-to face, build relationships and offer technical support. It also ensures that the Leatt brand is properly represented in the marketplace," added Macdonald.
Finally, the Company is actively pursuing its youth development program. Macdonald said, "We believe that attending amateur events and identifying talent early is critical to developing young athletes. These are the superstars of the future and we want them to be early adopters of our braces and our full line of protective gear."
Conference Call:
The Company will host a conference call at 10:00 am ET to discuss the 2016 first quarter results.
Participants should dial in to the call ten minutes before the scheduled time, using the following numbers: 1-888-348-8777 (USA) or +1-412-902-4245 (international) to access the call.
TIK Tel-Instrument Electronics Corp. Announces Receipt of $1.3 Million CRAFT 708 Army Order and a New Mode 5 IFF Test Set. http://finance.yahoo.com/news/tel-instrument-electronics-corp-announces-123000625.html